Subsequently, the clinical characterization of CRABP2 in ESCC tissues showed that downregulation of CRABP2 in T tissues was significantly correlated with the occurrence position, pathology, TNM stage, size, infiltration depth and cell differentiation of ESCC, suggesting that the expression of CRABP2 was likely to be an efficient indicator for the prognosis of ESCC. Here, CRABP2 is linked to esophageal squamous cell carcinoma.